ATHA Athira Pharma

Athira Pharma to Participate in Upcoming October Conferences

Athira Pharma to Participate in Upcoming October Conferences

BOTHELL, Wash., Sept. 28, 2023 (GLOBE NEWSWIRE) --  (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that Company management will participate in the following upcoming investor conferences in October.

Goldman Sachs Alzheimer’s Disease Day

Format: Panel Presentation

Date and Time: Tuesday, October 3, 2023, from 10:00 a.m. ET- 11:00 a.m. ET

Location: Goldman Sachs Conference Center, New York City

JonesTrading 2023 Healthcare Summit

Format: Investor Meetings

Investors interested in meeting with Athira management during the JonesTrading Conference, please reach out to your JonesTrading representative or contact Julie Rathbun at .

Dates: October 9-11

Location: Eden Roc, Miami

Jefferies Inaugural Biotech CNS/Neuro Summit

Format: Fireside Chat

Date and Time: Thursday, October 12, 2023, at 8:30 a.m. ET

Location: Jefferies Conference Center, New York City

Live webcasts of the panel and presentations can be accessed from the Investors section of the Athira website at . An archived replay of the webcasts will be available for at least 30 days following the event.

About Athira Pharma, Inc.

Athira Pharma, Inc., headquartered in the Seattle, Washington area, is a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration. Athira aims to alter the course of neurological disease by advancing its pipeline of therapeutic candidates targeting the neurotrophic HGF system for Alzheimer’s and Parkinson’s disease, Dementia with Lewy bodies, and amyotrophic lateral sclerosis. For more information, visit . You can also follow Athira on , , (formerly known as Twitter) and .

Investor & Media Contact:

Julie Rathbun

Athira Pharma



206-769-9219



EN
28/09/2023

Underlying

ATHAAthira Pharma

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Athira Pharma

 PRESS RELEASE
Free
ATHA ATHIRA PHARMA

LeonaBio Appoints Industry Veteran Mark F. Kubik as Chief Business Off...

LeonaBio Appoints Industry Veteran Mark F. Kubik as Chief Business Officer Brings more than 25 years of biopharma business development and corporate strategy expertise BOTHELL, Wash., Feb. 03, 2026 (GLOBE NEWSWIRE) -- LeonaBio, Inc. (NASDAQ: LONA), a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for diseases with high unmet medical needs, today announced the appointment of Mark F. Kubik as Chief Business Officer. In this role, Mr. Kubik will lead LeonaBio’s business development strategy and execution, with responsibility for licensing, partn...

February 3, 2026 1 EN
 PRESS RELEASE
Free
ATHA ATHIRA PHARMA

Athira Pharma Announces Name Change to LeonaBio, Inc. with New Ticker ...

Athira Pharma Announces Name Change to LeonaBio, Inc. with New Ticker “LONA” New name to reflect recent transformative acquisition of rights to Phase 3 program in metastatic breast cancer and commitment to continued leadership, resilience and innovation BOTHELL, Wash., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for diseases with high unmet medical needs, today announced that it has changed its name to LeonaBio, Inc. The name change aligns with the Company’s transforma...

January 9, 2026 1 EN
 PRESS RELEASE
Free
ATHA ATHIRA PHARMA

Athira Pharma Announces Exclusive License to Lasofoxifene Phase 3 Deve...

Athira Pharma Announces Exclusive License to Lasofoxifene Phase 3 Development Program for Metastatic Breast Cancer Candidate and a Financing for up to $236 Million Phase 3 Development Program of Novel Selective Estrogen Receptor Modulator (SERM) Represents Potential Multi-Billion Dollar Opportunity as Treatment Option for Patients with ESR1-Mutations Financing Co-Led by Commodore Capital, Perceptive Advisors and TCGX Supports Development of Lasofoxifene through Phase 3 Clinical Topline Data Readout and Regulatory Milestones Conference Call Today at 8:30 am Eastern Time BOTHELL, Wash., De...

December 18, 2025 1 EN
 PRESS RELEASE
Free
ATHA ATHIRA PHARMA

Athira Pharma Reports Third Quarter 2025 Financial Results and Provide...

Athira Pharma Reports Third Quarter 2025 Financial Results and Provides Business Update Continuing to explore strategic alternatives focusing on maximizing stockholder value   Presented results from Phase 1 clinical trial of ATH-1105 in healthy volunteers demonstrating a favorable safety and tolerability profile as well as dose proportional pharmacokinetics and CNS penetration, supporting continued clinical development  BOTHELL, Wash., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a clinical stage biopharmaceutical company focused on developing small molecules to...

November 6, 2025 1 EN
 PRESS RELEASE
Free
ATHA ATHIRA PHARMA

Athira Pharma Announces Reverse Stock Split

Athira Pharma Announces Reverse Stock Split BOTHELL, Wash., Sept. 11, 2025 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (“Athira” or “Company”) (NASDAQ: ATHA), a clinical stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that it will effect a 10-for-1 reverse stock split of Athira’s issued and authorized common stock. Athira’s stockholders previously approved the reverse stock split and granted the board of directors the authority to determine the exact split ratio and when to proceed with the reverse st...

September 11, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch